Citation Information :
Sinha P, Acharya S, Kumar S, Shukla S, Mohammad S. The Association of Cardiovascular Disease Risk in Polycystic Ovarian Syndrome: A Qualitative Systematic Review. J South Asian Feder Obs Gynae 2023; 15 (4):497-500.
Polycystic ovarian syndrome (PCOS) is a complex hormonal imbalance with increased amounts of androgen, luteinizing hormone, and insulin. It shows various symptoms like acne, hirsutism, irregular menstruation, and obesity. Besides these, it is accompanied by hyperinsulinemia, hyperandrogenism, hyperlipidemia, anovulation, and insulin resistance. More recently PCOS has been increasingly linked with the development of cardiovascular and thrombotic risks compared to normal women of the same age. According to research so far, PCOS women experience a considerable increase in oxidative stress (OS), which causes many of the metabolic and cardiovascular abnormalities that characterize this condition. In this article, we address the risks associated with both established and emerging cardiovascular risk factors, as well as the various research that suggests women with PCOS may be more susceptible for developing thrombosis and cardiovascular disease (CVD).
Duică F, Dănilă CA, Boboc AE, et al. Impact of Increased Oxidative Stress on Cardiovascular Diseases in Women with Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2021;12:614679. DOI: 10.3389/fendo.2021.614679.
Deligeoroglou E, Vrachnis N, Athanasopoulos N, et al. Mediators of chronic inflammation in polycystic ovarian syndrome. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 2012;28(12):974–978. DOI: 10.3109/09513590.2012.683082.
Mak W, Dokras A. Polycystic ovarian syndrome and the risk of cardiovascular disease and thrombosis. Semin Thromb Hemost 2009;35(7):613–620. DOI: 10.1055/s-0029-1242715.
Kondapaneni V, Gutlapalli SD, Poudel S, et al. Significance of homocysteine levels in the management of polycystic ovarian syndrome: A literature review. Cureus 2020;12(10):e11110. DOI: 10.7759/cureus.11110.
Wekker V, van Dammen L, Koning A, et al. Long-term cardiometabolic disease risk in women with PCOS: A systematic review and meta-analysis. Hum Reprod Update 2020;26(6):942–960. DOI: 10.1093/humupd/dmaa029.
Diamanti–Kandarakis E, Kandaraki E, Christakou C, et al. The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome. Obes Rev Off J Int Assoc Study Obes 2009;10(4):431–441. DOI: 10.1111/j.1467-789X.2009.00588.x.
Talbott EO, Zborowski J, Rager J, et al. Is there an independent effect of polycystic ovary syndrome (PCOS) and menopause on the prevalence of subclinical atherosclerosis in middle aged women? Vasc Health Risk Manag 2008;4(2):453–462. DOI: 10.2147/vhrm.s1452.
Pierard M, Tassin A, Conotte S, et al. Sustained intermittent hypoxemia induces adiponectin oligomers redistribution and a tissue-specific modulation of adiponectin receptor in mice. Front Physiol 2019;10:68. DOI: 10.3389/fphys.2019.00068.
Fauser BCJM, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012;97(1):28.e25–38.e25. DOI: 10.1016/j.fertnstert.2011.09.024.
Murri M, Luque–Ramírez M, Insenser M, et al. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): A systematic review and meta-analysis. Hum Reprod Update 2013;19(3):268–288. DOI: 10.1093/humupd/dms059.
Milne GL, Dai Q, Roberts LJ II. The isoprostanes—25 years later. Biochim Biophys Acta 2015;1851(4):433–445. DOI: 10.1016/j.bbalip.2014.10.007.
Calzada M, López N, Noguera JA, et al. Elevation of isoprostanes in polycystic ovary syndrome and its relationship with cardiovascular risk factors. J Endocrinol Invest 2019;42(1):75–83. DOI: 10.1007/s40618-018-0888-y.
Liu S, Navarro G, Mauvais–Jarvis F. Androgen excess produces systemic oxidative stress and predisposes to beta-cell failure in female mice. PloS One 2010;5(6):e11302. DOI: 10.1371/journal.pone.0011302.
Spritzer PM, Lecke SB, Satler F, et al. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction 2015;149(5):R219–R227. DOI: 10.1530/REP-14-0435.
Garoufi A, Pagoni A, Papadaki M, et al. Cardiovascular risk factors and subclinical atherosclerosis in Greek adolescents with polycystic ovary syndrome: Its relationship with body mass index. Child Basel Switz 2021;9(1):4. DOI: 10.3390/children9010004.
Herman R, Jensterle M, Janež A, et al. Genetic variability in antioxidative and inflammatory pathways modifies the risk for PCOS and influences metabolic profile of the syndrome. Metabolites 2020;10(11):E439. DOI: 10.3390/metabo10110439.
Pang X, Liu J, Zhao J, et al. Homocysteine induces the expression of C-reactive protein via NMDAr-ROS-MAPK-NF-κB signal pathway in rat vascular smooth muscle cells. Atherosclerosis 2014;236(1):73–81. DOI: 10.1016/j.atherosclerosis.2014.06.021.
Shah H, Jan MU, Altaf A, et al. Correlation of hyper-homocysteinemia with coronary artery disease in absence of conventional risk factors among young adults. J Saudi Heart Assoc 2018;30(4):305–310. DOI: 10.1016/j.jsha.2018.04.002.
Sathyapalan T, David R, Gooderham NJ, et al. Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis. Sci Rep 2015;5:16890. DOI: 10.1038/srep16890.
Lu H, Buchan RJ, Cook SA. MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc Res 2010;86(3):410–420. DOI: 10.1093/cvr/cvq010.
Deswal R, Dang AS. Dissecting the role of micro-RNAs as a diagnostic marker for polycystic ovary syndrome: A systematic review and meta-analysis. Fertil Steril 2020;113(3):661.e2–669.e2. DOI: 10.1016/j.fertnstert.2019.11.001.
